Laboratório de Micologia, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Laboratório de Pesquisa Clínica Em Dermatologia Infecciosa, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Braz J Microbiol. 2022 Mar;53(1):231-244. doi: 10.1007/s42770-021-00658-1. Epub 2021 Nov 26.
Sporotrichosis is a cosmopolitan subcutaneous mycosis caused by Sporothrix species. Recently, this mycosis has gained notoriety due to the appearance of new endemic areas, recognition of new pathogenic species, changes in epidemiology, occurrence of outbreaks, and increasing numbers of cases. The purpose of this study is to analyze the peculiarities of sporotrichosis cases in Brazil since its first report in the country until 2020. In this work, ecological, epidemiological, clinical, and laboratorial characteristics were compiled. A systematic review of human sporotrichosis diagnosed in Brazil and published up to December 2020 was performed on PubMed/MEDLINE, SciELO, Web of Science, and LILACS databases. Furthermore, animal sporotrichosis and environmental isolation of Sporothrix spp. in Brazil were also evaluated. The study included 230 papers, resulting in 10,400 human patients. Their ages ranged from 5 months to 92 years old and 55.98% were female. The lymphocutaneous form was predominant (56.14%), but systemic involvement was also notably reported (14.34%), especially in the lungs. Besides, hypersensitivity manifestations (4.55%) were described. Most patients had the diagnosis confirmed by isolation of Sporothrix spp., mainly from skin samples. Sporothrix brasiliensis was the major agent identified. HIV infection, cardiovascular diseases, and diabetes were the most common comorbidities. Cure rate was 85.83%. Concerning animal sporotrichosis, 8538 cases were reported, mostly in cats (90.77%). Moreover, 13 Sporothrix spp. environmental strains were reported. This review highlights the burden of the emergent zoonotic sporotrichosis in Brazil, reinforcing the importance of "One Health" based actions to help controlling this disease.
巴西 2020 年前播散性孢子丝菌病病例特点分析:一项综述
播散性孢子丝菌病是一种由申克孢子丝菌引起的世界性皮肤真菌病。近年来,由于新的地方性流行地区的出现、新的致病性物种的发现、流行病学变化、暴发的发生以及病例数量的增加,这种真菌病已引起广泛关注。本研究旨在分析巴西首例报告以来至 2020 年期间的播散性孢子丝菌病病例的特点。本工作收集了该病的生态学、流行病学、临床和实验室特征。对截至 2020 年 12 月在巴西诊断的人类播散性孢子丝菌病病例,通过在 PubMed/MEDLINE、SciELO、Web of Science 和 LILACS 数据库进行系统性综述。此外,还评估了巴西的动物孢子丝菌病和环境申克孢子丝菌分离。本研究共纳入 230 篇文献,涉及 10400 例人类患者。患者年龄从 5 个月至 92 岁不等,女性占 55.98%。最常见的是淋巴管皮肤型(56.14%),但也有明显的全身性受累(14.34%),特别是肺部。此外,还描述了过敏表现(4.55%)。大多数患者通过分离申克孢子丝菌来确诊,主要从皮肤样本中分离。鉴定的主要病原体是巴西申克孢子丝菌。HIV 感染、心血管疾病和糖尿病是最常见的合并症。治愈率为 85.83%。关于动物孢子丝菌病,共报告了 8538 例,主要发生在猫(90.77%)。此外,还报告了 13 株环境申克孢子丝菌。本综述强调了巴西新兴人畜共患病孢子丝菌病的负担,强调了基于“One Health”的行动对于控制该病的重要性。